A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance

(2021) Rosalynd Upton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis

(2020) Wenting Zhang et al.   Frontiers in Immunology

The CD47-SIRPα Immune Checkpoint

(2020) Meike E.W. Logtenberg et al.   IMMUNITY

Tumoral and paratumoral NK cells and CD8+ T cells of esophageal carcinoma patients express high levels of CD47

(2020) Zuzana Strizova et al.   Scientific Reports

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

(2019) Branimir I. Sikic et al.   JOURNAL OF CLINICAL ONCOLOGY

CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL

(2019) Renée Bouwstra et al.   Cancer Immunology Research

Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding

(2019) Robyn J. Puro et al.   MOLECULAR CANCER THERAPEUTICS

CD47-ligation induced cell death in T-acute lymphoblastic leukemia

(2018) Pascal Leclair et al.   Cell Death & Disease

ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile

(2018) Steven E. Kauder et al.   PLoS One

Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion

(2018) Xiaojuan Liu et al.   Cell Reports

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phagocytosis: A Fundamental Process in Immunity

(2017) Carlos Rosales et al.   Biomed Research International

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

(2016) Jonathan T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20

(2016) K. Weiskopf et al.   Cancer Immunology Research

Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals

(2015) M. N. McCracken et al.   CLINICAL CANCER RESEARCH

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

(2015) Jie Liu et al.   PLoS One

The CD47-SIRP  signalling system: its physiological roles and therapeutic application

(2014) Y. Murata et al.   JOURNAL OF BIOCHEMISTRY

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

(2013) D. Tseng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Eat-me signals: Keys to molecular phagocyte biology and “Appetite” control

(2011) Wei Li   JOURNAL OF CELLULAR PHYSIOLOGY

Recombinant antibody libraries and selection technologies

(2011) Heyue Zhou et al.   New Biotechnology

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells

(2008) Richard K. Tsai et al.   JOURNAL OF CELL BIOLOGY